BiVictriX Therapeutics PLC Expansion of Therapeutic Pipeline (4803C)
February 23 2022 - 2:00AM
UK Regulatory
TIDMBVX
RNS Number : 4803C
BiVictriX Therapeutics PLC
23 February 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
BiVictriX announces expansion of its therapeutic pipeline with
two additional drug discovery programmes
Alderley Park, 23 February 2022 - BiVictriX Therapeutics plc
(AIM: BVX), an emerging biotechnology company applying a novel
approach to develop next generation cancer therapies using insights
derived from frontline clinical experience, today announces the
expansion of the Company's therapeutic pipeline with two additional
programmes, BVX002 and BVX003, both entering the early stages of
drug development.
BVX002 and BVX003 target novel cancer-specific twin antigen
fingerprints, incorporating the Company's proprietary Bi-Cygni(R)
technology, alongside the established and validated Antibody Drug
Conjugate (ADC) mechanism-of-action, to form the next-generation of
Bi-Cygni(R) ADCs with superior cancer selectivity. These programmes
enable the targeting of several haematological and solid tumour
cancer indications and will be developed alongside BiVictriX's lead
asset, BVX001, which has a lead indication in Acute Myeloid
Leukaemia (AML). This pipeline expansion demonstrates the broad
utility of the Bi-Cygni(R) approach across a wide range of solid
tumour and haematological cancer types which constitute areas of
significant unmet medical need, and further highlights the
potential expansion of the platform in novel areas of
immuno-oncology.
The pipeline expansion follows the Company's recent filing of
four new patent applications to further strengthen its growing
intellectual property portfolio in the UK and internationally. The
patents, which will form part of a new patent family for BiVictriX,
relate to several novel cancer-specific antigen pairs or
"fingerprints" across a range of oncology indications, which have
been identified by the Company.
Tiffany Thorn, Chief Executive of BiVictriX, commented: "This is
an exciting announcement for the Company. The expansion of our
current therapeutic pipeline to include two additional programmes
moving into the early stages of development is a significant
milestone and enables BiVictriX to demonstrate the broad utility of
its promising new approach to cancer therapeutic development across
a wide range of difficult-to-treat cancers, including both solid
tumour and haematological indications that currently represent
areas of urgent unmet medical need. We are focused on working to
fast-track the development of these two new programmes alongside
our lead asset, BVX001, to reach early preclinical proof of concept
in the short to medium term."
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer Email: info@bivictrix.com
Iain Ross, Chairman
SP Angel Corporate Finance LLP (NOMAD Tel: +44 (0) 20 3470
and Broker) 0470
David Hignell, Caroline Rowe (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886
Broker) 2500
Rupert Dearden/Freddy Crossley/Emma
Earl
Consilium Strategic Communications
Mary-Jane Elliott, Genevieve Wilson, Tel: +44 (0) 20 3709 5700
Alex Gunter Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst eliminating
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target antigen co-expression fingerprints, or "twin
antigens", on tumour cells, which are largely absent from healthy
cells. Whereas this concept has been validated in a clinical
diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a
therapeutic setting.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens", across a broad range of cancer
indications including Diffuse Large B Cell Lymphoma, Acute Myeloid
Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The
Company is using these novel "twin-antigens" to develop more
effective and safer therapeutics to target cancers that are
expected to constitute orphan indications and currently constitute
areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEIFWEEESEEE
(END) Dow Jones Newswires
February 23, 2022 02:00 ET (07:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024